Search

Research

Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection

Given the rise of multidrug-resistant (MDR) Pseudomonas aeruginosa infections, alternative treatments are needed. Anti-pseudomonal phage therapy shows promise, but its clinical application is limited due to the development of resistance and a lack of biofilm penetration.

News & Events

New funding to accelerate AI personalised phage therapies

Wal-yan researchers have been awarded $500,000 for their innovative research, supported by the Western Australian Government’s Future Health Medical Research and Innovation (FHRI) Fund.